Why Is Myriad Genetics Still Filing Patent Suits for Breast-Cancer Tests?

The Supreme Court declared human genes unpatentable, but it didn’t free the market for genetic testing.

National Journal
Brian Resnick
Aug. 8, 2013, 8:28 a.m.

You can’t pat­ent a piece of the hu­man gen­ome, the Su­preme Court de­clared in a un­an­im­ous de­cision in June. So why, in the weeks after, did Myri­ad Ge­net­ics — the com­pany whose pat­ents were voided — sue a com­pet­it­or for pat­ent in­fringe­ment for test­ing for the very gene de­clared un­pat­entable by the Court?

Some back­ground: In the case, the As­so­ci­ation for Mo­lecu­lar Patho­logy brought suit against Myri­ad be­cause it thought it one com­pany shouldn’t have the sole rights to a seg­ment of the hu­man gen­ome — es­pe­cially when that seg­ment in­dic­ates a per­son’s breast-can­cer risk. The or­gan­iz­a­tion ar­gued that Myri­ad’s mono­poly of test­ing for the ma­lig­nant vari­ants of the BRCA1 and BRCA2 genes plugged up in­nov­a­tion in the sci­ence and drove up costs for pa­tients. Those with a cer­tain vari­ant of these genes have a 60 per­cent like­li­hood of de­vel­op­ing breast can­cer. If you re­call, the act­ress An­gelina Jolie dis­covered she was a car­ri­er for the gene, which promp­ted her to un­der­go a double mastec­tomy to void the risk.

The Su­preme Court largely agreed with the As­so­ci­ation for Mo­lecu­lar Patho­logy, de­clar­ing slices of the nat­ur­ally oc­cur­ring hu­man gen­ome un­fit for pat­ents. And right after the de­cision, two com­pan­ies — Ambry Ge­net­ics and Gene By Gene — saw an open­ing to start of­fer­ing the  breast-can­cer screen­ing tests that Myri­ad had been per­form­ing. And then Myri­ad sued … for pat­ent in­fringe­ment.

The short an­swer to how Myri­ad could jus­ti­fy its move is this: Sci­ence is so very com­plic­ated, and the Court ruled nar­rowly.

In its de­cision, the Su­preme Court main­tained that man-made cop­ies of hu­man DNA were still pat­entable. These pieces are called cDNA, which are slightly altered cop­ies of the nat­ur­ally oc­cur­ring genes. They are use­ful tools for ge­net­ic test­ing, since they can be used to re­lay a per­son’s ge­net­ic in­form­a­tion in a stable form. This bit of the rul­ing, in ef­fect, al­lows Myri­ad to still lay claim to much of the breast-can­cer test­ing.

Writ­ing in Sci­entif­ic Amer­ic­an, Megan Krench, a ge­net­i­cist, provides a more de­tailed an­swer (Read­er’s Di­gest ver­sion: While the Court took away Myri­ad’s castle, they left them the moat):

Why do Myri­ad’s pat­ent rights to cDNA mat­ter? There are sev­er­al reas­ons. First, cDNA is an im­port­ant re­search tool. For ex­ample, the ed­ited cDNA se­quence, not the longer DNA se­quence, is of­ten used to cre­ate an­im­al mod­els of dis­eases. Those mod­els are es­sen­tial for re­search­ing new treat­ments and cures. Without the li­cens­ing to BRCA1/2 cDNA, cer­tain can­cer re­search may be re­stric­ted to Myri­ad. Next, cDNA is crit­ic­al for de­vel­op­ing new dia­gnost­ic tests for ge­net­ic dis­orders. Since the BRCA1/2 genes them­selves are not pat­en­ted, it may be pos­sible for oth­er com­pan­ies to de­vel­op new ge­net­ic tests — but the pat­en­ted cDNA will make this pro­cess much more dif­fi­cult.

In all, after the Court’s de­cision, Myri­ad ar­gues in the doc­u­ments filed against Ambry, it has re­tained 515 of 520 pat­ent claims re­gard­ing the test.

This is­sue is go­ing to get an­oth­er go-around in the courts, as Ambry has coun­ter­sued, cit­ing an­ti­trust vi­ol­a­tions. A lot of money is at stake here for Myri­ad and its com­pet­it­ors. Ac­cord­ing to Ars Tech­nica, Myri­ad hauled in $57 mil­lion from the tests that can cost $3,000 or more. And the in­tro­duc­tion of com­pet­it­ors, however brief, pushed the mar­ket price way down: Ambry star­ted to sell the tests for $2,280; Gene by Gene offered a re­l­at­ive steal at $995. The ge­net­ic-test­ing in­dustry is on the verge of boom­ing, as I re­por­ted in June. By 2021, the na­tion­al costs for ge­net­ic test­ing could rise to $25 bil­lion. Right now, they are around $5 bil­lion.

What We're Following See More »
PROCEDURES NOT FOLLOWED
Trump Not on Ballot in Minnesota
3 days ago
THE LATEST
MOB RULE?
Trump on Immigration: ‘I Don’t Know, You Tell Me’
3 days ago
THE LATEST

Perhaps Donald Trump can take a plebiscite to solve this whole messy immigration thing. At a Fox News town hall with Sean Hannity last night, Trump essentially admitted he's "stumped," turning to the audience and asking: “Can we go through a process or do you think they have to get out? Tell me, I mean, I don’t know, you tell me.”

Source:
BIG CHANGE FROM WHEN HE SELF-FINANCED
Trump Enriching His Businesses with Donor Money
5 days ago
WHY WE CARE

Donald Trump "nearly quintupled the monthly rent his presidential campaign pays for its headquarters at Trump Tower to $169,758 in July, when he was raising funds from donors, compared with March, when he was self-funding his campaign." A campaign spokesman "said the increased office space was needed to accommodate an anticipated increase in employees," but the campaign's paid staff has actually dipped by about 25 since March. The campaign has also paid his golf courses and restaurants about $260,000 since mid-May.

Source:
QUESTIONS OVER IMMIGRATION POLICY
Trump Cancels Rallies
5 days ago
THE LATEST

Donald Trump probably isn't taking seriously John Oliver's suggestion that he quit the race. But he has canceled or rescheduled rallies amid questions over his stance on immigration. Trump rescheduled a speech on the topic that he was set to give later this week. Plus, he's also nixed planned rallies in Oregon and Las Vegas this month.

Source:
‘STRATEGY AND MESSAGING’
Sean Hannity Is Also Advising Trump
6 days ago
THE LATEST

Donald Trump's Fox News brain trust keeps growing. After it was revealed that former Fox chief Roger Ailes is informally advising Trump on debate preparation, host Sean Hannity admitted over the weekend that he's also advising Trump on "strategy and messaging." He told the New York Times: “I’m not hiding the fact that I want Donald Trump to be the next president of the United States. I never claimed to be a journalist.”

Source:
×